Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NewAmsterdam Pharma

Request full access

Developing transformative, clinically validated oral therapies for patients with metabolic diseases

Naarden, NetherlandsFounded 2019Biotech & Life Sciences

About NewAmsterdam Pharma

NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company that focuses on the research and development of transformative oral therapies for major cardiometabolic diseases.

The company is investigating obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, as the preferred LDL-c-lowering therapy for high-risk cardiovascular disease (CVD) patients. The company's pipeline also includes a fixed-dose combination of obicetrapib and ezetimibe, which is in a Phase 2 clinical trial (ROSE2). NewAmsterdam is also conducting two Phase 3 pivotal trials, BROADWAY and BROOKLYN, to evaluate obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD). A third Phase 3 trial, PREVAIL, is designed as a cardiovascular outcomes trial. The company was founded in 2019 and is headquartered in Naarden, the Netherlands.

Source: Dealroom company data

At a glance

Status
Listed
Listing
Public via SPAC 2022

NewAmsterdam Pharma in the Naarden ecosystem

Live from Dealroom

The NewAmsterdam Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Series B and later8 investors entered at this stage

  • EQT Life Sciences
  • Frazier Healthcare Partners
  • Bain Capital Life Sciences
  • Panacea Venture
  • RA Capital Management
  • GMT Capital
  • Medicxi
  • Frazier Lifesciences Acquisition Corporation
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See NewAmsterdam Pharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.